Dong-A ST focuses on ethical drugs, such as domestically developed new drugs like Stillen, Zydena, and Motilitone, medical devices, diagnosis, and overseas businesses.
With its optimized research infrastructures such as its world-class, sophisticated research center completed in 2011, as well as its excellent researchers, Dong-A ST is furthering its efforts to develop global new drugs. Also, with the backing of these infrastructures, Dong-A ST vows to positively explore overseas markets, to expand its overseas exports, and to establish itself as a global pharmaceutical company, operating beyond the domestic market.
Company Details
- Employees
- 62
- Founded
- -
- Address
- 64, Cheonho-Daero, Dongdaemun-Gu, Seoul,korea, Republic Of
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.donga-st.com/
- HQ
- seoul
Dong-A St Questions
Dong-A St's website is http://www.donga-st.com/
Dong-A St's LinkedIn profile is https://www.linkedin.com/company/dong-a-st
Dong-A St has
62 employees.
View email and phone details for 62
employees at Dong-A St.
Dong-A St's industry is
Pharmaceutical Manufacturing
Dong-A St's top competitors are
Samsung Bioepis,
Lotte Biologics,
Jonlnbio,
Pharmbio Korea,
Celltrion Inc,
Samsung Biologics,
Daewon Pharmaceutical Co Ltd,
Dong-A Pharmaceutical Co.,ltd,
Metavia,
Ahn-Gook Pharmaceutical Co Ltd.
Dong-A St's categories are Pharmaceutical Manufacturing
Dong-A St's founding year is 2013
